Table 2. PJP cases Age, y/sex . Prior... | American Society of Hematology

Table 2.

PJP cases

Age, y/sex	Prior treatments	Therapy	Ibrutinib duration at time of PJP, mo	Steroid use within preceding 30 d	IgG level at time of infection	Symptoms	Diagnostic tests		PJP therapy	Outcome
Age, y/sex	Prior treatments	Therapy	Ibrutinib duration at time of PJP, mo	Steroid use within preceding 30 d	IgG level at time of infection	Symptoms	Chest CT scan	β-d-glucan level	PJP therapy	Outcome
Case 1
75/male	None: randomized to ibrutinib-alone arm of phase 3 trial	Ibrutinib single agent	1.1	None	Data not available	Fever, cough, dyspnea, fatigue	Diffuse bilateral patchy ground-glass opacities	289	TMP-SMX + prednisone for 21 d; ibrutinib held	Following PJP treatment, ibrutinib and PJP prophylaxis were resumed; symptoms resolved without subsequent recurrence of PJP
Case 2
80/female	F/FR/PCR	Ibrutinib single agent	2.7	None	272	Fever, dyspnea, hypoxia (oxygen saturation 88% on room air)	Diffuse bilateral patchy ground-glass opacities	171	TMP-SMX + prednisone for 21 d; ibrutinib held	Following PJP treatment, ibrutinib and PJP prophylaxis were resumed; symptoms resolved without subsequent recurrence of PJP
Case 3
62/female	None: enrolled in clinical trial of frontline therapy	iFCR	30.6	None	166	Fever, dyspnea, hypoxia (oxygen saturation 82% on room air)	Diffuse bilateral patchy ground-glass opacities	394	TMP-SMX + prednisone for 21 d; ibrutinib held	Following PJP treatment, ibrutinib and PJP prophylaxis were resumed; symptoms resolved without subsequent recurrence of PJP

Age, y/sex	Prior treatments	Therapy	Ibrutinib duration at time of PJP, mo	Steroid use within preceding 30 d	IgG level at time of infection	Symptoms	Diagnostic tests		PJP therapy	Outcome
Age, y/sex	Prior treatments	Therapy	Ibrutinib duration at time of PJP, mo	Steroid use within preceding 30 d	IgG level at time of infection	Symptoms	Chest CT scan	β-d-glucan level	PJP therapy	Outcome
Case 1
75/male	None: randomized to ibrutinib-alone arm of phase 3 trial	Ibrutinib single agent	1.1	None	Data not available	Fever, cough, dyspnea, fatigue	Diffuse bilateral patchy ground-glass opacities	289	TMP-SMX + prednisone for 21 d; ibrutinib held	Following PJP treatment, ibrutinib and PJP prophylaxis were resumed; symptoms resolved without subsequent recurrence of PJP
Case 2
80/female	F/FR/PCR	Ibrutinib single agent	2.7	None	272	Fever, dyspnea, hypoxia (oxygen saturation 88% on room air)	Diffuse bilateral patchy ground-glass opacities	171	TMP-SMX + prednisone for 21 d; ibrutinib held	Following PJP treatment, ibrutinib and PJP prophylaxis were resumed; symptoms resolved without subsequent recurrence of PJP
Case 3
62/female	None: enrolled in clinical trial of frontline therapy	iFCR	30.6	None	166	Fever, dyspnea, hypoxia (oxygen saturation 82% on room air)	Diffuse bilateral patchy ground-glass opacities	394	TMP-SMX + prednisone for 21 d; ibrutinib held	Following PJP treatment, ibrutinib and PJP prophylaxis were resumed; symptoms resolved without subsequent recurrence of PJP

CT, computed tomography; F, fludarabine; FCR, fludarabine, cyclophosphamide, rituximab; FR, fludarabine, rituximab; IgG, immunoglobulin G; PCR, pentostatin, cyclophosphamide, rituximab.